Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 60 - 80 |
| Updated: | 5/5/2016 |
| Start Date: | August 2015 |
| End Date: | March 2016 |
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of CNP520 in Healthy Elderly Subjects
The study will determine the safety of CNP520 in healthy elderly over 3 months. Data
relevant for Pharmacokinetic/Pharmacodynamic modeling will be obtained in order to define
the target dose in subsequent efficacy studies.
relevant for Pharmacokinetic/Pharmacodynamic modeling will be obtained in order to define
the target dose in subsequent efficacy studies.
Key Inclusion Criteria:
- Healthy status
- Body weight: ≥45kg
- BMI: 18-34 kg/m2
Key Exclusion Criteria:
- History or presence of any clinically significant disease of any major system organ
class.
- Heavy smoker status
- History /presence of clinically significant neurological or psychiatric disorders
- Any medical condition that might lead to or is associated with any cognitive deficit
- History or presence of severely impaired renal function
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials